212 related articles for article (PubMed ID: 35260100)
1. PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial.
Ménard C; Young S; Zukotynski K; Hamilton RJ; Bénard F; Yip S; McCabe C; Saad F; Brundage M; Nitulescu R; Bauman G
BMC Cancer; 2022 Mar; 22(1):251. PubMed ID: 35260100
[TBL] [Abstract][Full Text] [Related]
2. Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
Staal FHE; Janssen J; Brouwer CL; Langendijk JA; Ng Wei Siang K; Schuit E; de Jong IJ; Verzijlbergen JF; Smeenk RJ; Aluwini S
BMC Cancer; 2022 Apr; 22(1):416. PubMed ID: 35428210
[TBL] [Abstract][Full Text] [Related]
3. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial.
Petit C; Delouya G; Taussky D; Barkati M; Lambert C; Beauchemin MC; Clavel S; Mok G; Paré AG; Nguyen TV; Duplan D; Keu KV; Saad F; Juneau D; Ménard C
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):779-787. PubMed ID: 36639035
[TBL] [Abstract][Full Text] [Related]
6. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
[TBL] [Abstract][Full Text] [Related]
7. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
[TBL] [Abstract][Full Text] [Related]
8.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
9.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
10. Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques.
Rowe LS; Harmon S; Horn A; Shankavaram U; Roy S; Ning H; Lindenberg L; Mena E; Citrin DE; Choyke P; Turkbey B
Radiat Oncol; 2021 Feb; 16(1):32. PubMed ID: 33568190
[TBL] [Abstract][Full Text] [Related]
11.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
12. The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature.
Eissa A; Elsherbiny A; Coelho RF; Rassweiler J; Davis JW; Porpiglia F; Patel VR; Prandini N; Micali S; Sighinolfi MC; Puliatti S; Rocco B; Bianchi G
Minerva Urol Nefrol; 2018 Oct; 70(5):462-478. PubMed ID: 29664244
[TBL] [Abstract][Full Text] [Related]
13. 3-Year Freedom from Progression After
Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
[No Abstract] [Full Text] [Related]
14. Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
Calais J; Zhu S; Hirmas N; Eiber M; Hadaschik B; Stuschke M; Herrmann K; Czernin J; Kishan AU; Nickols NG; Elashoff D; Fendler WP
BMC Cancer; 2021 May; 21(1):512. PubMed ID: 33962579
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
16.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
17. Intention-to-Treat Analysis of
Schwenck J; Olthof SC; Pfannenberg C; Reischl G; Wegener D; Marzec J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
J Nucl Med; 2019 Oct; 60(10):1359-1365. PubMed ID: 30850491
[TBL] [Abstract][Full Text] [Related]
18. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.
Fendler WP; Calais J; Eiber M; Flavell RR; Mishoe A; Feng FY; Nguyen HG; Reiter RE; Rettig MB; Okamoto S; Emmett L; Zacho HD; Ilhan H; Wetter A; Rischpler C; Schoder H; Burger IA; Gartmann J; Smith R; Small EJ; Slavik R; Carroll PR; Herrmann K; Czernin J; Hope TA
JAMA Oncol; 2019 Jun; 5(6):856-863. PubMed ID: 30920593
[TBL] [Abstract][Full Text] [Related]
19.
Bowden P; See AW; So K; Lawrentschuk N; Moon D; Murphy DG; Rao R; Crosthwaite A; King D; Haxhimolla H; Grummet J; Ruljancich P; Gyomber D; Landau A; Campbell N; Frydenberg M; Smyth LML; Nolan S; Gwini SM; McKenzie DP
World J Urol; 2021 Nov; 39(11):4117-4125. PubMed ID: 34076753
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml.
Witkowska-Patena E; Giżewska A; Dziuk M; Miśko J; Budzyńska A; Walęcka-Mazur A
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):343-348. PubMed ID: 31780781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
